B-type natriuretic Peptide assay for the diagnosis and prognosis of patent ductus arteriosus in preterm infants.
ABSTRACT Patent ductus arteriosus (PDA) is a significant cause of morbidity and mortality in preterm infants. Measurement of plasma B-type natriuretic peptide (BNP) has been reported to be a useful bedside screening tool for the presence of hemodynamically significant PDA (hsPDA) in neonates. This study was conducted to investigate the usefulness of a BNP assay as a biochemical marker for the diagnosis of hsPDA and predictive biomarker of the response to indomethacin in preterm infants.
Preterm infants born at <37 weeks' gestational age were prospectively enrolled within 24 hours of birth. Plasma BNP levels were measured on days 1, 4, and 7. Significant PDA was diagnosed by large ductal flow with left to right shunt on color Doppler echocardiography, along with clinical features of PDA. Following that, hsPDA was treated with indomethacin.
A total of 28 preterm infants were prospectively enrolled in this study. Seven infants with PDA had higher on day 4 plasma BNP values (median 654.68 pg/mL; range 428.29-1280.00) compared to the control group (median 124.52 pg/mL; range 37.21-290.49). The area under the receiver operator characteristic curve for the detection of hsPDA was high: 0.998 (95% confidence interval: 0.995-1.002). The cutoff of BNP concentration for the diagnosis of hsPDA was determined to be 412 pg/mL (sensitivity: 100%; specificity: 95%).
B-type natriuretic peptide can be a useful biomarker for the screening and diagnosis of PDA in preterm infants. Serial BNP measurements are valuable for assessing the clinical course and indomethacin responsiveness of PDA.
- SourceAvailable from: Namasivayam Ambalavanan[Show abstract] [Hide abstract]
ABSTRACT: Pulmonary hypertension is common in bronchopulmonary dysplasia and is associated with increased mortality and morbidity. This pulmonary hypertension is due to abnormal microvascular development and pulmonary vascular remodeling resulting in reduced cross-sectional area of pulmonary vasculature. The epidemiology, etiology, clinical features, diagnosis, suggested management, and outcomes of pulmonary hypertension in the setting of bronchopulmonary dysplasia are reviewed. In summary, pulmonary hypertension is noted in a fifth of extremely low birth weight infants, primarily those with moderate or severe bronchopulmonary dysplasia, and persists to discharge in many infants. Diagnosis is generally by echocardiography, and some infants require cardiac catheterization to identify associated anatomic cardiac lesions or systemic-pulmonary collaterals, pulmonary venous obstruction or myocardial dysfunction. Serial echocardiography and B-type natriuretic peptide measurement may be useful for following the course of pulmonary hypertension. Currently, there is not much evidence to indicate optimal management approaches, but many clinicians maintain oxygen saturation in the range of 91 to 95%, avoiding hypoxia and hyperoxia, and often provide inhaled nitric oxide, sometimes combined with sildenafil, prostacyclin, or its analogs, and occasionally endothelin-receptor antagonists. Birth Defects Research (Part A), 2014. © 2014 Wiley Periodicals, Inc.Birth Defects Research Part A Clinical and Molecular Teratology 03/2014; · 2.27 Impact Factor
Copyright © 2012 The Korean Society of Cardiology
Korean Circulation Journal
Patent ductus arteriosus (PDA) refers to the persistent patency
of the ductus arteriosus after birth. In most term infants, the duc-
tus arteriosus closes during the first 48 hours after birth. However,
in many small preterm infants the ductus remains open allowing
an increasing systemic-to-pulmonary shunt as the pulmonary vas-
cular resistance falls.1) In premature infants, the ductus frequently
Print ISSN 1738-5520 • On-line ISSN 1738-5555
B-Type Natriuretic Peptide Assay for the Diagnosis and Prognosis
of Patent Ductus Arteriosus in Preterm Infants
Joon Sik Kim, MD and Eun Jung Shim, MD
Department of Pediatrics, Hallym University Sacred Heart Hospital, College of Medicine, Hallym University, Anyang, Korea
Background and Objectives: Patent ductus arteriosus (PDA) is a significant cause of morbidity and mortality in preterm infants. Mea-
surement of plasma B-type natriuretic peptide (BNP) has been reported to be a useful bedside screening tool for the presence of hemody-
namically significant PDA (hsPDA) in neonates. This study was conducted to investigate the usefulness of a BNP assay as a biochemical
marker for the diagnosis of hsPDA and predictive biomarker of the response to indomethacin in preterm infants.
Subjects and Methods: Preterm infants born at <37 weeks’ gestational age were prospectively enrolled within 24 hours of birth. Plasma
BNP levels were measured on days 1, 4, and 7. Significant PDA was diagnosed by large ductal flow with left to right shunt on color Doppler
echocardiography, along with clinical features of PDA. Following that, hsPDA was treated with indomethacin.
Results: A total of 28 preterm infants were prospectively enrolled in this study. Seven infants with PDA had higher on day 4 plasma BNP values
(median 654.68 pg/mL; range 428.29-1280.00) compared to the control group (median 124.52 pg/mL; range 37.21-290.49). The area under
the receiver operator characteristic curve for the detection of hsPDA was high: 0.998 (95% confidence interval: 0.995-1.002). The cutoff of
BNP concentration for the diagnosis of hsPDA was determined to be 412 pg/mL (sensitivity: 100%; specificity: 95%).
Conclusion: B-type natriuretic peptide can be a useful biomarker for the screening and diagnosis of PDA in preterm infants. Serial BNP
measurements are valuable for assessing the clinical course and indomethacin responsiveness of PDA. (Korean Circ J 2012;42:192-196)
KEY WORDS: Patent ductus arteriosus; B-type natriuretic peptide; Echocardiography.
Received: September 9, 2011
Revision Received: October 4, 2011
Accepted: October 8, 2011
Correspondence: Eun Jung Shim, MD, Department of Pediatrics, Hallym
University Sacred Heart Hospital, College of Medicine, Hallym University,
896 Pyeongchon-dong, Dongan-gu, Anyang 431-070, Korea
Tel: 82-31-380-3730, Fax: 82-31-380-1685
• The authors have no financial conflicts of interest.
This is an Open Access article distributed under the terms of the Creative
Commons Attribution Non-Commercial License (http://creativecommons.
org/licenses/by-nc/3.0) which permits unrestricted non-commercial use,
distribution, and reproduction in any medium, provided the original work
is properly cited.
fails to undergo spontaneous closure due to the elevated sensitivi-
ty of the ductal tissue to the dilating effects of prostaglandins and
low sensitivity to the effects of oxygen.2) As a result, the ductus of
preterm infants can remain open for many days, and although it
may constrict initially, it frequently reopens.3) PDA has been recogniz-
ed as a cause of significant comorbidity in premature infants. In ad-
dition to pulmonary congestion and heart failure caused by the left-
to-right shunt of PDA, clinical sequelae of the ductal steal of blood
from the PDA present high risks of intraventricular hemorrhage,4) br-
onchopulmonary dysplasia,5) pulmonary hemorrhage,6) renal hypo-
perfusion,7) necrotizing enterocolitis, and death.8) Therefore, early di-
agnosis of hemodynamically significant PDA (hsPDA) allows early
treatment and probable reduction of morbidity in preterm infants.6)9)
Because physical examination may be unreliable for determining
the presence and magnitude of PDA in premature infants, echo-
cardiography is used to document PDA shunting. However, routine
echocardiography for the evaluation of PDA in premature infants
has certain disadvantages, such as high cost, discomfort, disruption
of the neonatal environment, and limited availability in some cen-
ters.10) Moreover, the hemodynamic effect of a PDA may be difficult
Joon Sik Kim, et al.
to determine even by using echocardiography, and the clinical co-
urse cannot be predicted reliably.11)
B-type natriuretic peptide (BNP) is a cardiac natriuretic hormone,
mainly produced by the cardiomyocytes and is characterized by di-
uretic, natriuretic and vasodilatatory properties. In particular, BNP is
produced by ventricular cells in response to volume expansion and
pressure load and in cardiac heart failure.12)13) BNP antagonizes the
renin-angiotensin-aldosterone system, and reduces intravascular
volume, and ventricular preload and afterload. It has been associat-
ed with the regulation of pulmonary vasculature, possibly including
the ductus arteriosus.14)
B-type natriuretic peptide can be a useful bedside screening tool
for the presence of hsPDA in premature infants.15) Recent studies
have further demonstrated the potential of BNP to guide an indo-
methacin therapeutic strategy for these patients.16)
We evaluated the clinical usefulness of the measurement of pl-
asma BNP levels in preterm infants. For accurate diagnosis of hsP-
DA, we performed repeated BNP level measurements and determin-
ed the best cut-off value of BNP on day 4 of life and the change in
BNP level after treatment with indomethacin for predicting hsPDA.
Subjects and Methods
This prospective study was conducted at the neonatal intensive
care unit of Hallym University Sacred Heart Hospital. Preterm infants
born at <37 weeks’ gestational age (GA) were eligible for entry into
the study. The infants were enrolled within 24 hours of birth. Pre-
term infants with congenital anomalies, cardiac abnormalities other
than patent foramen ovale, and intraventricular hemorrhage oc-
curring before 48 hours of life were excluded from this study. Thirty-
three preterm infants were initially enrolled during a 5-month pe-
riod (from April 2009 to August 2009). The data of 5 infants were
excluded from analysis because the data were incomplete. Twenty-
eight infants (12 male, 16 female) were eligible for evaluation. Their
mean GA was 32.7 weeks (range: 28.4-35.8 weeks) and the mean
birth weight was 1918 g (range: 1080-2830 g). We prospectively
evaluated the infants for PDA within the first 7 days of life and ad-
ministered indomethacin if hsPDA was diagnosed based on a large
ductal flow with left to right shunt on color Doppler echocardiography.
Measurement of plasma B-type natriuretic peptide level
Blood samples for BNP level were collected by umbilical venous
catheter aspiration or from the peripheral vein and were transferred
into ethylenediaminetetraacetic acid tubes. Blood samples were
taken on days 1, 4, and 7 after birth. BNP concentrations were de-
tected using a commercial diagnostics system (Aggott achitect BNP
assay, Abbott Diagnostics, Abbott Park, IL, USA).
A GE Vivid 7 Dimension cardiovascular ultrasound machine with
curvilinear 8 MHz transducer incorporating color-flow, pulsed-wave,
and continuous-wave Doppler was used (GE Healthcare, Fairfield, CT,
USA). A two-dimensional color flow Doppler echocardiography was
performed on all infants within the fourth day of life for assessment
of PDA and to rule out congenital heart disease. A significant PDA
was diagnosed based on the presence of a large ductal flow with
left to right shunt with retrograde flow in the descending aorta, as
demonstrated on the two-dimensional color Doppler echocardio-
graph.17-19) To estimate the magnitude of left to right shunting ac-
ross the PDA, a ratio of the diameters of the left atrial to aortic root
(LA/AO) was evaluated in the parasternal long axis view at the level
of the aortic valve. The infants with hsPDA were treated with three
doses of indomethacin.20) Follow-up echocardiography was perform-
ed on day 8 of life by one investigator to avoid inter-observer vari-
Diagnosis of hemodynamically significant
patent ductus arteriosus
Hemodynamically significant PDA was diagnosed if the infant
fulfilled the echocardiographic criteria and had at least 3 of the
following 6 clinical signs of cardiovascular dysfunction including 1)
systolic or continuous murmur at the left sterna edge, 2) increased
precordial impulse, 3) bounding peripheral pulses, 4) resting tachy-
cardia, 5) unexplained deterioration of the respiratory status, and 6)
increased pulmonary vascular markings and cardiac enlargement
or signs of pulmonary edema on the chest radiograph. The echocar-
diographic criteria included 1) LA/AO diameter ratio >1.4. 2) Diastolic
turbulence (backflow) on the Doppler echocardiograph of the pul-
monary artery, and 3) ductal diameter of PDA >1.4 mm.21)
Indomethacin (Indocin®, Merck Sharp and Dohme, West Point, PA,
USA) was given as a 60-minute intravenous infusion at 24-hour in-
tervals for each course (3 doses). For the initial indomethacin dose,
0.2 mg/kg was administered to all patients regardless of their age.22)
For the second or third dose, 0.1 mg/kg was administered when the
patient was <48 hours old, and 0.2 mg/kg was administered when
the patient was 2 to 7 days old, respectively.
Statistical analysis was performed using Statistical Package for
the Social Sciences (SPSS) version 15.0 (SPSS Inc., Chicago, IL, USA).
Continuous variables are presented as mean values with standard
194 The Usefulness of B-Type Natriuretic Peptide Assay in Patent Ductus Arteriosus
deviation. We used the Fisher’s exact test to compare categorical
variables and the Mann-Whitney’s rank sum U test to compare con-
tinuous variables. The Mann-Whitney’s rank-sum U test was used
to calculate the differences of BNP levels between the groups. Re-
ceiver operator characteristic (ROC) analysis was performed to de-
termine the best cut-off values of plasma BNP levels for the detec-
tion of significant PDA. A p<0.05 was considered significant.
Clinical characteristics of infants in the control and
hemodynamically significant patent ductus arteriosus groups
For a 5-month period, 28 preterm infants (12 male, 16 female)
were prospectively enrolled in our study. Of the 28 infants, 21 in-
fants had no hsPDA (control group, mean GA: 32.83 weeks; mean
birth weight: 1930 g). The remaining 7 infants had hsPDA, which re-
quired treatment with indomethacin (hsPDA group, mean GA: 32.18
weeks; mean birth weight: 1850 g). The characteristics of the infants
in these 2 groups are summarized in Table 1. No significant differ-
ences were observed in GA, birth weight, sex, or delivery type.
B-type natriuretic peptide levels in the control and
hemodynamically significant patent ductus arteriosus group
This study showed a significant correlation between BNP levels on
day 4 of life and presence of PDA in preterm infants (Table 2). On
day 4 of life, the mean BNP concentration in the hsPDA group was
significantly higher than that in the control group (median 654.68
vs. 124.52 pg/mL; p<0.001) (Fig. 1). Seven infants in the hsPDA gr-
oup showed clinical symptoms, such as continuous murmur at the
left sterna edge, resting tachycardia, and tachypnea. on day 8 of life,
the 7 infants in the hsPDA group became asymptomatic after the
administration of 3 doses of indomethacin. All the infants in the
hsPDA group completed their therapy with a single treatment co-
urse (3 doses), and without the need for a second course of indo-
methacin. At the second echocardiographic evaluation (on day 8
of life), the ductus of 5 infants in the hsPDA group were closed. In
the remaining 2 infants with hsPDA, ductal shunt was reduced and
ductal closure was confirmed 7 days later. After treatment with in-
domethacin, the BNP levels in the hsPDA group decreased signifi-
cantly (median 654.68 vs. 288.48 pg/mL; p<0.001).
In the control group 18 infants demonstrated a progressive fall in
plasma BNP level from day 1 to day 7. The remaining 3 control gr-
oup infants demonstrated an initial fall and subsequent rise in the
plasma BNP level. Upon reviewing the clinical records of these lat-
ter infants, they had late onset sepsis between day 4 and day 7 of
life. All subjects in the hsPDA group had no sepsis by day 7 of life. In
this study, there was no preterm infant with pulmonary hypertension.
At the first echocardiographic evaluation, a significant correla-
tion was observed between the LA/AO diameter ratios and BNP
levels (r=0.812; p<0.001) (Fig. 2).
Table 1. Characteristics of infants in the control and hsPDA groups
Gestational age (week)32.83±2.22
Birth weight (kg)1.93±0.49
Caesarean section (%)14 (67)
Values are expressed as numbers (%) of infants or means±SD. NS: not signifi-
cant, hsPDA: hemodynamically significant patent ductus arteriosus
Table 2. BNP levels in the control and hsPDA groups (pg/mL)
7 day 75.46±65.16
Values are expressed as means±SD. hsPDA: hemodynamically significant
patent ductus arteriosus, BNP: B-type natriuretic peptide
Fig. 2. Correlation between LA/AO ratio and BNP level. BNP levels correlated
positively with the LA/AO ratio (r=0.812; p< 0.001). BNP: B-type natriuretic
peptide. LA: left atrium, AO: aorta.
0 0.5 1 1.5 2
Fig. 1. Plasma B-type natriuretic peptide (BNP) values on days 1, 4 and 7 of
life. PDA: patent ductus arteriosus.
Day of life
0 1 2 3 4 5 6 7 8
Values for infants with significant PDA Values for “well” infants
Joon Sik Kim, et al.
The area under the ROC curve for the detection of PDA was sta-
tistically significant at 0.998 (95% confidence interval: 0.995-
1.002). The level of plasma BNP on day 4 of life was a highly sensi-
tive indicator of hsPDA (sensitivity 100%; specificity 95%) with a
cutoff value of 412 pg/mL (Fig. 3).
B-type natriuretic peptide has a 32 amino acid ring structure. It
acts on a cyclic guanosine monophosphate-coupled receptor via a
transmembrane domain.23) The ventricles of the heart are the main
site of BNP synthesis and release in response to volume and pres-
sure loading, as well as ventricular stress.12)13)
B-type natriuretic peptides have a major role in the screening and
diagnosis of cardiac disease and monitoring of the treatment resp-
onse in children and adults. Recent studies have concentrated on
the potential use of these markers in pediatric and neonatal medi-
cine. In all neonates, BNP concentrations increase on day 1 of life and
show a typical peak, even in the absence of a significant patent of
the ductal arteriosus, and subsequently decrease with chronological
age.24) The BNP levels in preterm infants were higher than in healthy
term infants during the first few days after birth. In particular, when
PDA is present in preterm infants, the BNP concentration is abnor-
mally high and reflects the magnitude of shunting through the PDA.
Holmström et al.11) reported that plasma levels of natriuretic pep-
tides in preterm infants are strongly related to the hemodynamic in-
fluence of PDA. Since then, plasma natriuretic peptide levels, in-
cluding increased BNP levels, were studied to determine the pres-
ence of hsPDA in preterm infants. Flynn et al.10) showed that BNP
levels strongly correlated with ductal size in premature neonates.
We measured the plasma BNP levels in preterm infants during the
first 7 days of life. On day 4 of life, plasma BNP levels in infants with
hsPDA were significantly higher than in infants without hsPDA, al-
though the primary limitation of this study was its small sample size.
The best cutoff BNP concentration on day 4 of life was 412 pg/mL;
sensitivity was 100%, and specificity was 95%. Flynn et al.10) showed
that the best cutoff of BNP concentration is 300 pg/mL and a lower
cutoff of 105 pg/mL for infants at >2 days of life. Lee et al.25) sh-
owed that the best cutoff at 24 hours of age is 468.5 pd/mL and at
48 hours of age is 935 pg/mL. In another study, the best cutoff BNP
concentration on day 3 of life was 1110 pg/mL.26)
Hsu et al.27) reported that the mean BNP levels decreased signifi-
cantly in response to indomethacin. They classified as responders
and non-responders in preterm infants with PDA. After treatment
with indomethacin, the mean BNP levels in the responders decreased
significantly from the baseline 24 hours after the final dose, wh-
ereas the BNP levels in the non-responders did not change signifi-
cantly. We could not conduct a comparative study of indomethacin
responsiveness because all the hsPDAs closed after indomethacin
administration. Moreover, in our study, the sample size was smaller,
the birth weights were larger, and the GA was higher than in the pre-
vious study. However, our results demonstrated that the mean BNP
level in the hsPDA group decreased significantly after indomethacin
treatment. Moreover, significantly decreasing BNP levels predicted
a good response to indomethacin treatment and ductal closure.
In this study, 3 infants in the control group, with increased BNP
concentration from day 4 to 7, had late onset sepsis but a lower
mean BNP concentration on day 7 compared with the hsPDA group.
In animal studies, plasma BNP levels have been shown to rise with
induced endotoxemia, and the pro-inflammatory cytokine interleu-
kin-6 has been linked with BNP production.28) In patients with severe
sepsis or septic shock, BNP levels are highly elevated. In a compar-
ative study on children with sepsis and those with acute left ven-
tricular dysfunction, BNP levels were found to be higher in the lat-
ter group. Therefore, BNP serves as a marker for cardiac dysfunction
associated with sepsis in preterm neonates.29)30)
Echocardiography is the main method used to detect PDA in new-
borns. Although BNP may not replace echocardiography for the di-
agnosis of PDA, it may obviate the need to perform repeated echo-
cardiography in order to confirm ductal closure after treatment. BNP
measurement can be used as an adjunct to echocardiography for
diagnosing PDA. Although it is not a stand-alone test, the BNP as-
say is an immediate method for providing valuable information that
indicates whether an infant requires intervention for PDA, and de-
termines the clinical course of PDA in a preterm infant. BNP may
be a useful screening tool for detecting the presence of a PDA in
premature neonates, because levels of BNP are higher in the pres-
ence of a significant patent ductus. In addition, serial BNP mea-
surements may be of value in assessing the clinical course of PDA
and a possible alternative to repeated echocardiography in the di-
agnosis and management of PDA in preterm infants.
Fig. 3. Receiver operator characteristic curve determines the B-type natri-
uretic peptide cutoff value for detecting hemodynamically significant patent
ductus arteriosus in preterm infants.
0.00 0.25 0.50 0.75 1.00
196 The Usefulness of B-Type Natriuretic Peptide Assay in Patent Ductus Arteriosus
1. Bancalari E, Claure N, Gonzalez A. Patent ductus arteriosus and respi-
ratory outcome in premature infants. Biol Neonate 2005;88:192-201.
2. Clyman RI. Ductus arteriosus: current theories of prenatal and post-
natal regulation. Semin Perinatol 1987;11:64-71.
3. Heymann MA, Rudolf AM. Control of the ductus arteriosus. Physiol
4. Clyman RI. Mechanisms regulating the ductus arteriosus. Biol Neo-
5. Rojas MA, Gonzalez A, Bancalari E, Claure N, Poole C, Silva-Neto G.
Changing trends in the epidemiology and pathogenesis of neonatal
chronic lung disease. J Pediatr 1995;126:605-10.
6. Kluckow M, Evans N. Ductal shunting, high pulmonary blood flow, and
pulmonary hemorrhage. J Pediatr 2000;137:68-72.
7. Hammerman C. Patent ductus arteriosus: clinical relevance of pros-
taglandins and prostaglandin inhibitors in PDA pathophysiology and
treatment. Clin Perinatol 1995;22:457-79.
8. Cotton RB, Stahlman MT, Kovar I, Catterton WZ. Medical management
of small preterm infants with symptomatic patent ductus arteriosus.
J Pediatr 1978;92:467-73.
9. Walther FJ, Benders MJ, Leighton JO. Persistent pulmonary hyperten-
sion in premature neonates with severe respiratory distress syndrome.
10. Flynn PA, da Graca RL, Auld PA, Nesin M, Kleinman CS. The use of a
bedside assay for plasma B-type natriuretic peptide as a biomarker in
the management of patent ductus arteriosus in premature neonates.
J Pediatr 2005;147:38-42.
11. Holmström H, Hall C, Thaulow E. Plasma levels of natriuretic peptides
and hemodynamic assessment of patent ductus arteriosus in preterm
infants. Acta Paediatr 2001;90:184-91.
12. Daniels LB, Maisel AS. Natriuretic peptides. J Am Coll Cardiol 2007;50:
13. Cantinotti M, Clerico A, Murzi M, Vittorini S, Emdin M. Clinical relev-
ance of measurement of brain natriuretic peptide and N-terminal pro-
brain natriuretic peptide in pediatric cardiology. Clin Chim Acta 2008;
14. Reynolds EW, Ellington JG, Vranicar M, Bada HS. Brain-type natriure-
tic peptide in the diagnosis and management of persistent pulmonary
hypertension of the newborn. Pediatrics 2004;114:1297-304. Erratum
in: Pediatrics 2005;115:1454.
15. Puddy VF, Amirmansour C, Williams AF, Singer DR. Plasma brain na-
triuretic peptide as a predictor of haemodynamically significant pat-
ent ductus arteriosus in preterm infants. Clin Sci (Lond) 2002;103:
16. Attridge JT, Kaufman DA, Lim DS. B-type natriuretic peptide concen-
trations to guide treatment of patent ductus arteriosus. Arch Dis Child
Fetal Neonatal Ed 2009;94:F178-82.
17. Evans N. Diagnosis of patent ductus arteriosus in the preterm new-
born. Arch Dis Child 1993;68(1 Spec No):58-61.
18. Skelton R, Evans N, Smythe J. A blinded comparison of clinical and
echochardiographic evaluation of the preterm infant for patent duc-
tus arteriosus. J Paediatr Child Health 1994;30:406-11.
19. Skinner J. Diagnosis of patent ductus arteriosus. Semin Neonatol 2001;
20. Tammela O, Ojala R, Iivainen T, et al. Short versus prolonged indometh-
acin therapy for patent ductus arteriosus in preterm infants. J Pediatr
21. El Hajjar M, Vaksmann G, Rakza T, Kongolo G, Storme L. Severity of the
ductal shunt: a comparison of different markers. Arch Dis Child Fetal
Neonatal Ed 2005;F90:419-22.
22. Young TE, Mangum B. Neofax: a Manual of Drugs Used in Neonatal
Care. 20th ed. Montvale, NJ: Thompson Healthcare; 2007.
23. Levin ER, Gardner DG, Samson WK. Natriuretic peptides. N Engl J Med
24. Da Graca RL, Hassinger DC, Flynn PA, Sison CP, Nesin M, Auld PA. Lon-
gitudinal changes of brain-type natriuretic peptide in preterm neo-
nates. Pediatrics 2006;117;2183-9.
25. Lee HS, Choi WS, Choi BM, et al. Usefulness of B-type natriuretic pep-
tide assay in predicting symptomatic patent ductus arteriosus in pre-
term infants. J Korean Soc Neonatol 2004;11:44-53.
26. Choi BM, Lee KH, Eun BL, et al. Utility of rapid B-type natriuretic pep-
tide assay for diagnosis of symptomatic patent ductus arteriosus in
preterm infants. Pediatrics 2005;115:e255-61.
27. Hsu JH, Yang SN, Chen HL, Tseng HI, Dai ZK, Wu JR. B-type natriuretic
peptide predicts responses to indomethacin in premature neonates
with patent ductus arteriosus. J Pediatr 2010;157:79-84.
28. Tomaru Ki K, Arai M, Yokoyama T, et al. Transcriptional activation of the
BNP gene by lipopolysaccharide is mediated through GATA elements
in neonatal rat cardiac myocytes. J Mol Cell Cardiol 2002;34:649-59.
29. Ueda S, Nishio K, Akai Y, et al. Prognostic value of increased plasma
levels of brain natriuretic peptide in patients with septic shock. Shock
30. El-Khuffash A, Molloy EJ. Are B-type natriuretic peptide (BNP) and N-
terminal-pro-BNP useful in neonates? Arch Dis Child Fetal Neonatal